Spiro Medical

Company

Last mentioned: Mar 6, 2026

Timeline

  1. Bioelectronic Medicine Forum

    The forum convenes in NYC to discuss the future of neural interfaces.

  2. Keynote Announcement

    Iota Biosciences founder announced as the lead speaker for the NYC Forum.

  3. Astellas Acquisition

    Astellas Pharma acquires Iota Biosciences to bolster its Rx+ electronics division.

Stories mentioning Spiro Medical 1

pharma Neutral

Iota Biosciences Founder to Keynote 2026 Bioelectronic Medicine Forum

The founder of Iota Biosciences will headline the 2026 Bioelectronic Medicine Forum in New York, marking a pivotal moment for the neurotechnology sector. The event will feature a global cohort of innovators, including European firms Coherence Neuro and Graphenicalab, alongside U.S. startup Spiro Medical.

7 sources

About Spiro Medical coverage

This page surfaces every story mentioning Spiro Medical across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where Spiro Medical was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.